Influence of Preexisting Diabetes on Postoperative Clinical Outcomes and Trajectory in Patients Undergoing Lumbar Fusion: Cohort Matched Analysis

Kevin C Jacob, Madhav Patel, Timothy J Hartman, James Nie¹, Alexander W Parsons, Keith R. Macgregor², Omolabake Oyetayo¹, Eileen Zheng, Kern Singh²

¹Rush University Medical Center, ²Midwest Orthopaedics At Rush

INTRODUCTION: While prior studies have assessed the role of diabetes on outcomes following lumbar spine fusion, the strength of their conclusions have been limited by the absence of inclusion of differing fusion techniques as well as absence of cohort matching for inherent demographic differences at baseline. We aim to compare perioperative and postoperative mean patient-reported outcome measures (PROMs) and minimum clinically important difference (MCID) achievement following anterior lumbar interbody fusion (ALIF), lateral lumbar interbody fusion (LLIF) and transforaminal lumbar interbody fusion (TLIF) in patients stratified by pre-existing diabetes in a cohort matched study design.

METHODS: A retrospective review of a prospectively maintained attending academic single-surgeon database was conducted for lumbar procedures between June 2005 and December 2021. Inclusion criteria was set as primary, elective, single-level or multi-level lumbar fusion procedures for degenerative lumbar spinal pathology. Patients undergoing surgery indicated for infectious, malignant, or traumatic etiologies were excluded. Patient demographics, perioperative characteristics, complications, and PROMs were collected. PROMs were administered at preoperative and 6-week, 12-week, 6-month, 1-year, and 2-year postoperative time-points and included Visual Analogue Scale (VAS) for back and leg pain, Oswestry Disability Index (ODI), and 12-Item Short Form Physical and Mental Composite Score (SF-12 PCS/MCS). Patients were grouped into two cohorts, depending on pre-existing diabetic status preoperatively. Propensity score matching was conducted to account for baseline differences between cohorts. Following matching, demographic, perioperative characteristics, and mean PROMs were compared among groups using inferential statistics. Postoperative improvement from preoperative baseline within each cohort was assessed with paired samples t-test. Achievement of Minimum Clinical Important Difference (MCID) was determined by comparing ΔPROM scores to previously established threshold values. MCID achievement rates were compared between groups with chi-squared analysis.

RESULTS: Following matching, no significant differences existed between cohorts with exception for difference of preexisting diabetes preoperatively. Significantly greater rates of altered mental status were noted in diabetic patient cohort (p =0.034). Preoperative mean PROM scores were similar for all PROMs collected. Cohorts demonstrated no significant mean postoperative differences for all PROMs collected with exception of VAS leg at 12-weeks and 6-months and SF-12 PCS at 12-weeks, (p ≤0.019, all). Non-diabetic patient cohort demonstrated improvement from respective preoperative baseline to the 2-year time point for all PROMs collected at all individual postoperative timepoints with the exception of SF-12 MCS at 2-years, and SF-12 PCS at 6-weeks (p ≤0.044, all). Diabetic patient cohort demonstrated significant improvement from respective preoperative baseline to 2-year time point for all PROMs collected at all individual postoperative timepoints with the exception of VAS back at 2-years, ODI at 6-weeks and 2-years, SF-12 MCS 6-weeks and 2-years, and SF-12 PCS at 6 and 12-weeks (p ≤0.049, all). Both cohorts achieved overall MCID greater than 50% in VAS back, VAS leg, ODI, and SF-12 PCS. No significant differences were noted between cohort rate of achievement of a MCID.

DISCUSSION AND CONCLUSION: Results for our study may suggest inferior short term (6-week) postoperative improvement for disability, mental health, and physical function as well decreased ability to maintain long term (2-year) post-operative progress for back pain and disability in diabetics undergoing lumbar fusion. These patients may also suffer from inferior clinical outcomes for leg pain in the intermediate postoperative period (12-weeks-6-months).

n n <t< th=""><th>- Contraction of the second second</th><th colspan="8">Table 2 Toppenet Company</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th colspan="4">LADIE 5. MCILD ACTIONETICIE</th></t<>	- Contraction of the second second	Table 2 Toppenet Company															LADIE 5. MCILD ACTIONETICIE								
		Total	Non-Diabetic	Disbetic	'p-salar							Total	Non-Diabetic	Diabetic	*p-value			Nep-			*p-		N	P	
n n <th></th> <th>(a-238)</th> <th>(a=197)</th> <th>(**8I)</th> <th></th> <th></th> <th>Total</th> <th>Neg-Diabetic</th> <th>Diabetic</th> <th>*p-value</th> <th>Concerning and and</th> <th>C</th> <th>1. 100</th> <th>1</th> <th></th> <th></th> <th></th> <th>Distants</th> <th></th> <th></th> <th>- the second sec</th> <th></th> <th>Non-Diapetic</th> <th>Dispetic</th> <th>-p-value</th>		(a-238)	(a=197)	(**8I)			Total	Neg-Diabetic	Diabetic	*p-value	Concerning and and	C	1. 100	1				Distants			- the second sec		Non-Diapetic	Dispetic	-p-value
	Arctinean (SD)	57.8 × 10.9	57.7 = 11.3	58.0 + 10.1	0.852		(ac216)	(00157)	(autilit)		Complication	(B=2.98)	(8*157)	(0~01)				Distances/			14146				
	finder					And and the state of the state			14.000		Reintabation	0.0%(0)	0.0%(0)	0.0%(0)				Pest-		Diabetic					
nm nm <t< td=""><td>Estada</td><td>22.255.060</td><td>22,455,6435</td><td>27.255 (225)</td><td>4.978</td><td>Spinss removely</td><td></td><td>and the second second</td><td></td><td></td><td>Deiners Batention</td><td>0.28/ (22)</td><td>8.00 (1.0)</td><td>0.001 (00)</td><td>0.600</td><td></td><td></td><td>operative</td><td></td><td>Post-operative</td><td></td><td>VAS Back</td><td></td><td></td><td></td></t<>	Estada	22.255.060	22,455,6435	27.255 (225)	4.978	Spinss removely		and the second second			Deiners Batention	0.28/ (22)	8.00 (1.0)	0.001 (00)	0.600			operative		Post-operative		VAS Back			
	ht-1	22.281 (2.20)	22 00 000	22 881 1000		Central Sumous	69.1% (212)	89,8% (1+1)	N.25(01)	0.634	Consey Meterization	7.674(64)	6.5% (Fa)	2.224(6)	0.809		Mary Distants	BD CO I	This has been as the	DECOM.		6-modes	65 7%	47.0%	0.241
	Date March Law Concerns	16.74(13)	76875 (170	74.875 (197)		Foraminal Stonesis	30.7% (73)	29:9%(47)	32.1% (26)	0.732	Urinary Tract Infection	1.3%(3)	1.9% (3)	0.0% (0)	0.211		Ann Daneos	PROM	Dissector	PROM		1. August	50.001	43.001	0.041
All set state	thing many mark caregory					Degenerative					Acute Renal Endure	1.3%(7)	1.256(2)	1.2%(f)	0.979		Mean +SD	insprovement.	Mean +SD	Inspect center.		12-weeks	60.87%	34.47%	0.243
	(1011)		ALC: NO. 1		0.309	Spondylolisthesis	49.6% (118)	47.8% (75)	53.1% (43)	0.437	Alterned Monital States	3.001 (7)	1,201,473	6.281.765	0.034	VAS Back						6-months	58.8%	57.8%	0.887
	<20 xb.m.	37,854 (90)	38,254 (80)	37,054 (20)		Influence				0.145	Antice Section Solution	4.374(7)	1.374(a)	0.679(2)	0.004	Reconstinue	66+74		64.22		0.607	1	10 000	43.04	0.047
m m <td>530 kg/m/</td> <td>63.2%(145)</td> <td>41.8% (97)</td> <td>63.0% (51)</td> <td></td> <td>Spondyfoliathosia</td> <td>21.4%(51)</td> <td>24,2% (38)</td> <td>16.1% (13)</td> <td></td> <td>VTE</td> <td>0.0% (0)</td> <td>0.0% (0)</td> <td>0.0%(0)</td> <td></td> <td>1 roopenante</td> <td></td> <td></td> <td>0.4</td> <td></td> <td>0.007</td> <td>1-year</td> <td>43.07*</td> <td>41.276</td> <td>0.867</td>	530 kg/m/	63.2%(145)	41.8% (97)	63.0% (51)		Spondyfoliathosia	21.4%(51)	24,2% (38)	16.1% (13)		VTE	0.0% (0)	0.0% (0)	0.0%(0)		1 roopenante			0.4		0.007	1-year	43.07*	41.276	0.867
	Body Mass Index (Mean #					Recurrent Hermitted					Pulmonary Embolism	0.0%(0)	0.0%(.0%)	0.0%(0)		O-WEEKS	3.9 ± 2.8	40.001	4.1 = 2.3	40.001	0.572	2-year	40.0%	42.9%	0.862
	SD)				0.676	Nucleus Polyness	13.0%(31)	11.9% (18)	16 125 (13)	0.323	Descention	0.00/ 100	0.000 (0)	0.001.000		12-weeks	3.5 ± 2.7	<0.001	3.9 ± 2.7	<0.001	0.364	Onostall	72 6% (111)	70.0% (56)	0.687
Name		32.7 ± 6.3	32.6 ± 6.7	32.9 + 5.6		Descention Functions	13.08/ (315)	14 704 (777)	13 46 (100)		FIRCHIPPERPEAK	9,979 (97	0.074 (07	0.0%(0)		6-months	35+28	<0.001	33+25	<0.001	0.650	orean	72.074(111)	10/0/11(20)	0.002
	Dheicity					English Broughury	17.94(19)	14.775 (27)	12/03 (10)	0.434	Pneumonia	0.4%(1)	0.6%(1)	0.0%(0)	0.472	1 courses	10+10	-10.001	24+22	0.003	0.560	VAS Leg			
	Cancesian	74475(176)	26,425 (120)	69.315 (56)		T BE BE THE BEAU	ALC: NO. OF CO.	100 Mar 17 Mar	AL 10.101		Atelecturia	0.4%(1)	0.6%(0)	0.0%(0)	0.472	1-9-44	2.7 . 4.7	-0.001	24-22	0.045	0.000	6 marks	45.6%	34.450	0.280
	African American	11.3%(22)	11.8% (38)	11.1% (%)		MIS-1LIF (2)	10.255 (187)	09.4% (199)	71.8% (58)	0.671	Discord Killeniam	0.001.000	0.001 (0)	0.001.000		2-year	4.5 ± 3.1	0.005	5.0 ± 3.0	0.281	0.660	0-models	40.074		
 All and all all all all all all all all all al	Winner	# 775 J 7773	8 221 (775)	11,125,000		ALLE (3)	D.5%(02)	12.7%(20)	14.8% (12)		P DOM OF A STREET, A	0,0/4 (0)	0.074 (0)	0.0/4(0)		VASLet						12-weeks	20.87%	43.875	0.218
	Asian	7.255 (5)	185.00	3,855,775	A-011	LLIF (4)	16.4% (39)	17.8% (28)	13.4% (11)		Amhythmia	0.4%(1)	0.0% (0)	1.2%(1)	0.163	Propagation	56+29		55+26		0.917	6-months	59.7%	45.5%	0.172
Impair main Impai	Ohim	1.451.000	1.001.075	6.781.000		Faxing Level				0.165	llens	2.9%(7)	3.2%(5)	2.5%(2)	0.757	Tropenare	274 - 274		0.0 - 0.0		4.011		61 AA.		
	Cual Contract	24400	12400	647(0)		L1-L2	0.4%(1)	0.6% (D)	9.0% (D)		Manager (Manufalace	8.68/ (21)	8.00/ (1.0)	8.681.675	0.017	0-weeks	3.2 ± 3.0	<0.001	3.7 ± 2.5	0.009	0.409	1-year	51.37%	41.276	0.487
	Service Service		ALC: 10.1			1114	0.4%(1)	0.0%(0)	125(0)		reausea) vonning	0.074(41)	8.5%(14)	×054(1)	0.943	12-weeks	2.4 ± 2.5	<0.001	3.7 ± 3.0	0.003	0.016	2-year	47.6%	69.2%	0.217
	Num-Stracker	77.7% (185)	79.876 (125)	74,175 (90)	0.330	1513	12540	195(0)	125(0)		Hernatorna	0.4%(1)	0.6%(1)	0.0%(0)	0.472	6 months	2.2 ± 2.6	<0.001	36+30	0.001	0.019	Onomall	61.15(/\$5)	66 786 (78)	0.538
	Marker	22.3%(55)	20.4% (0.2)			1111	1.14/ (1)	2,000,000	2.00.00		Dysphagia	0.8%(2)	0.6%(1)	1.2% (D)	0.632	1	10.11	-8.001	20.23	0.003	0.027	Crtain .	01.174(20)	00.774 (20)	0.356
	Diabetes					1000	1.554 (55	1.574 (2)	10000		Enum of Unhamon Origin	16.10/ (26)	14.000 (222)	12.30 (10)	0.605	1-year	3.0 = 3.1	-4.001	2.9 = 3.1	0.042	0.930	ODI			
	Nan-Diabetic	66.9% (157)	100.0% (157)	0.0% (0)	-8.001	12-13	0.855122	1.3%121	432510		Perti te Cultiona Origan	1.17.174(70)	1 14/2/0 (ee)	1.172201100	0.505	2-year	4.1 ± 3.2	0.001	3.2 ± 3.3	0.003	0.450	6 marks	70 2%	21.056	0.425
	Diabetic	34.0% (81)	0.0% (0)	100.0% (81)		LD-LA	6.1%(15)	8.9%(1+)	2,4% (2)		VIE = venous thromboernb	OINT				ODI									
Display	Hyperbeneive Status					13-15	4.0%(11)	4.5%(7)	4.9%(4)		Presseling calculated with this	Learning for cat-	and invited and the			Reconstitute	41.6 + 12.4		48.4 - 17.1		0.220	12-weeks	41.3%	29.4%	0.234
	Nan-Byperiensing	29,4% (70)	28.7% (45)	30.5% (25)	9.724	14-1.5	42.6% (100)	36.9% (58)	51.9%(42)		Babd/and indicates statistics	- square too car	contra camoora			ritopaante			40.44 - 17.1		0.220	6-months	60.5%	54.1%	0.512
	Hamericanics	70.4%(168)	71.7%(117)	69.316 (56)		14-81	185.00	3.155.001	125(0)		Bottinee indicates statistica	u signikarke.				O-WEEKS	35.6 ± 20.3	0.013	41.5 = 17.9	0.589	0.149				
	ASA Classification					153	17 855 (200)	10.051(02)	14,455 (28)							12-weeks	27.3 ± 18.7	<0.001	34.2 ± 16.6	<0.001	0.066	1-year	47.5%	37.5%	0.496
$\frac{1}{2} \sum_{i=1}^{n} \frac{1}{16 + 10^{i}} \sum_{i=1}^{n} \frac{1}{16 + 10^{$	a	\$7.1% (T16)	60.551 (85)	55,651,010	A 144	TINE	0.000	8.980 x 84	1.10.10							6-months	216 ± 20.0	=0.001	26.6 ± 16.4	+10.001	0.422	2.sver	45.5%	38 5%	0.686
$ \frac{1}{1000} \frac{1}{100$	21	47.851.(107)	20.021.0021	20.451.000		Number of Londs			14/100	0.016						1	20.4 + 22.7	-8.001	11.1 - 24.7	0.003	0.641	Ownerall	65 685 (61)	\$9.19/(216)	0.461
Distribution Distribution<		42.57411445	27274042			Planates of Leven				0.403						1-year	47/4 = 44.7		20.3 - 22.3	0.002	0.041	Critian	07.078(01)	29.174 (20)	0.401
$\frac{1}{1} \frac{1}{1} \frac{1}$	Mull ASA SORE	24110	24110	23195	0.145	Openated										2-year	32.7 ± 27.2	0.044	36.3 ± 20.6	0.165	0.666	SE-12 MCS			
$\frac{1}{1000} \frac{1}{1000} \frac{1}{1000$	invariance					Single Level (9)	89.0% (211)	87.9% (138)	91.3% (73)							SE-12 MCS						6 marks	22.69/	21.484	0.540
$\frac{1}{1000} \frac{1}{1000} \frac{1}{1000$	Medicare Medicard	18,1% (43)	20.4% (02)	13.8% (11)		Multiple Levels (1)	11.0% (26)	12.15 (19)	\$.\$%(7)							Propagation	47.5 ± 11.7		47.4 ± 12.6		0.021	0-weeks	27.3074	21/4/6	0.040
All All <td>Warkers' Compensation</td> <td>29,8% (71)</td> <td>28.7% (43)</td> <td>32.1% (26)</td> <td>0.428</td> <td>Operative Time (mean</td> <td></td> <td></td> <td></td> <td>0.799</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1 roopenante</td> <td>47.2 . 11.7</td> <td></td> <td>41.4 = 15.0</td> <td></td> <td>0.701</td> <td>12-weeks</td> <td>32.1%</td> <td>23.1%</td> <td>0.401</td>	Warkers' Compensation	29,8% (71)	28.7% (43)	32.1% (26)	0.428	Operative Time (mean				0.799						1 roopenante	47.2 . 11.7		41.4 = 15.0		0.701	12-weeks	32.1%	23.1%	0.401
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Privale	32.176 (124)	51,0%4 (805)	54,375 (44)		aND min)	150.2 ± 71.2	149.3 ± 70.1	151.9 ± 73.6							O-WEEKS	21.2 ± 12.1	40.001	30.2 = 15.3	0.204	0.710	6-months	34.0%	34.8%	0.948
Space Base 100 Base 100 Base 100 Base 100 Space Space </td <td>ASA - American Society a</td> <td>f Azerthesiologists</td> <td></td> <td></td> <td></td> <td>Estimated Blood Loss</td> <td></td> <td></td> <td></td> <td>0.966</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>12-weeks</td> <td>53.4 ± 11.4</td> <td>-0.001</td> <td>51.9 ± 14.1</td> <td>0.009</td> <td>0.612</td> <td>1</td> <td>36.681</td> <td>23.684</td> <td>0.700</td>	ASA - American Society a	f Azerthesiologists				Estimated Blood Loss				0.966						12-weeks	53.4 ± 11.4	-0.001	51.9 ± 14.1	0.009	0.612	1	36.681	23.684	0.700
Marke scheme stander dipulses Tage: Tripuls Tripuls Tage: Tripuls <t< td=""><td colspan="5">*s-value calculated with Student's t-text for continuous variables and chi-secure for categorical variables (secure 450 ml) (secure 450 ml) (secure 450 ml)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>6-months.</td><td>51.0 ± 10.8</td><td>r# 001</td><td>51.1 ± 12.3</td><td>0.649</td><td>0.500</td><td>1-year</td><td>30.07%</td><td>31.079</td><td>0.705</td></t<>	*s-value calculated with Student's t-text for continuous variables and chi-secure for categorical variables (secure 450 ml) (secure 450 ml) (secure 450 ml)											6-months.	51.0 ± 10.8	r# 001	51.1 ± 12.3	0.649	0.500	1-year	30.07%	31.079	0.705				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Boldfare indicates statistical similarity and a statistical similarity of the states o					91.1 1 197.0	1000 1 116.7	0.149						Lange	51.0 ± 10.2	0.601	49.8 + 12.0	0.004	0.455	2-year	15.6%	0.0%	0.232		
$ \frac{1}{100} 1$						Excipation and party (concern				0.179						1-9-244	21.7 1 10.5	0.001	40.00014.0	0.004	0.400	Owwall	40.38/ (27)	44.49/ (3.6)	0.630
Name No. No. <td></td> <td></td> <td></td> <td></td> <td></td> <td>+5D (hours)</td> <td>54.2 + 38.8</td> <td>31.6 ± 30.9</td> <td>59.3 + 42.2</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>2-year</td> <td>50.5 ± 11.8</td> <td>0.709</td> <td>54.1±11.7</td> <td>0.597</td> <td>0.428</td> <td>Overan</td> <td>47.374 (37)</td> <td>447474 (10)</td> <td>0.049</td>						+5D (hours)	54.2 + 38.8	31.6 ± 30.9	59.3 + 42.2							2-year	50.5 ± 11.8	0.709	54.1±11.7	0.597	0.428	Overan	47.374 (37)	447474 (10)	0.049
Note: Note: <th< td=""><td></td><td></td><td></td><td></td><td></td><td>Past-operative Day of</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>SE-12 PCS</td><td></td><td></td><td></td><td></td><td></td><td>SF-12 PCS</td><td></td><td></td><td></td></th<>						Past-operative Day of										SE-12 PCS						SF-12 PCS			
$\frac{100}{100} \frac{100}{100} $						Discharge (POD)										Propagation	31.0 + 8.0		28.1 + 6.6		0.072	6 maaks	40.4%	20.1%	0.025
JOS JAS (m) JAS (m) <thjas (m)<="" th=""> <thjas (m)<="" th=""> <thjas (<="" td=""><td></td><td></td><td></td><td></td><td></td><td>POD0</td><td>4,4% (10)</td><td>4.6%(7)</td><td>3.9%(3)</td><td>0.515</td><td></td><td></td><td></td><td></td><td></td><td>f marks</td><td>31.6 - 0.6</td><td>0.767</td><td>20.0 - 0.0</td><td>0.004</td><td>0.166</td><td>10 Inclus</td><td>40.474</td><td>10.010</td><td>0.723</td></thjas></thjas></thjas>						POD0	4,4% (10)	4.6%(7)	3.9%(3)	0.515						f marks	31.6 - 0.6	0.767	20.0 - 0.0	0.004	0.166	10 Inclus	40.474	10.010	0.723
Test Test (1) Test (2) Test (2) <thtest (2)<="" th=""> Test (2) <tht< td=""><td></td><td></td><td></td><td></td><td></td><td>PODI</td><td>38.4% (88)</td><td>42.5% (65)</td><td>29.9%(23)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0-946682</td><td>31.3 × 6.3</td><td>0.787</td><td>20.0 = 0.0</td><td>0.994</td><td>9.100</td><td>12-weeks</td><td>63.07*</td><td>37.776</td><td>0.607</td></tht<></thtest>						PODI	38.4% (88)	42.5% (65)	29.9%(23)							0-946682	31.3 × 6.3	0.787	20.0 = 0.0	0.994	9.100	12-weeks	63.07*	37.776	0.607
Note: Note: <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>12-weeks</td><td>36.4 ± 9.1</td><td><0.001</td><td>29.2 ± 8.3</td><td>0.388</td><td><0.001</td><td>6-months</td><td>64.0%</td><td>69.6%</td><td>0.642</td></th<>																12-weeks	36.4 ± 9.1	<0.001	29.2 ± 8.3	0.388	<0.001	6-months	64.0%	69.6%	0.642
Display Display <t< td=""><td></td><td></td><td></td><td></td><td></td><td>POD2</td><td>26.5% (61)</td><td>24,2%(37)</td><td>31.2% (24)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>6-months</td><td>38.7 ± 11.5</td><td><0.001</td><td>352 ± 113</td><td><0.001</td><td>0.226</td><td>1</td><td>60.041</td><td>CO. 88-1</td><td>0.003</td></t<>						POD2	26.5% (61)	24,2%(37)	31.2% (24)							6-months	38.7 ± 11.5	<0.001	352 ± 113	<0.001	0.226	1	60.041	CO. 88-1	0.003
Total LAND LAND Same 2000 Model and and galaxies 2000 Model and						P003	17.4%(40)	16.2%(25)	18.5% (15)							Looper	28 5 + 12 1	<0.001	155=96	0.007	0.101	1-year	68.379	08.476	0.992
Discoperti Volta Discoperative Volta DiscoperatiVolta Discoperative Volta Dis						PODA	645710	5.955 (8)	1.65(10)							1.944	2000 - 1011		20.2 - 2.0		4.000	2-year	65.6%	87.5%	0.227
Mark 1/1 1/2 <td></td> <td></td> <td></td> <td></td> <td></td> <td>Destinguishing MAX Role</td> <td></td> <td>10.100</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>2-year</td> <td>38.9 ± 13.1</td> <td>0.001</td> <td>36.9 ± 11.0</td> <td>0.002</td> <td>0.684</td> <td>Ownedl</td> <td>79 481 (69)</td> <td>82.226 (200)</td> <td>0.542</td>						Destinguishing MAX Role		10.100								2-year	38.9 ± 13.1	0.001	36.9 ± 11.0	0.002	0.684	Ownedl	79 481 (69)	82.226 (200)	0.542
NOME 0.1.1 0.1.2 0.1.1 0.1.2 Nomen Vacuum 1.1.3 0.1.1 0.1.2 Nomen Vacuum 1.1.3 0.1.1 0.1.2 Nomen Vacuum 1.1.3 0.1.1 0.1.2 Nomen Vacuum Nomen Vacuum Nomen Vacuum Nomen Vacuum Nomen V						runayoutre v AS Fills										*n-value calca	olated using Stud	ent's tatest betwo	en eroens			Unuali	re.w/s (28)	State (30)	0.42
NOM 0.11 0.14 0.14 0.14 0.14 Month of the state o						50000										Robbinsindi	owner statistical s	mifines	an george			*e-value calculate	d with chi-squared anal	vsis	
DOI: DOI: <thdoi:< th=""> DOI: DOI: <thd< td=""><td></td><td></td><td></td><td></td><td></td><td>1000</td><td>5.0 ± 1.9</td><td>3.2 ± 2.0</td><td>4.8 + 1.8</td><td>0.128</td><td></td><td></td><td></td><td></td><td></td><td>secolitice into</td><td>NAME AND ADDRESS OF</td><td>gunnanice.</td><td></td><td></td><td></td><td>Baldford indicate</td><td>a statistical set size (Property)</td><td></td><td></td></thd<></thdoi:<>						1000	5.0 ± 1.9	3.2 ± 2.0	4.8 + 1.8	0.128						secolitice into	NAME AND ADDRESS OF	gunnanice.				Baldford indicate	a statistical set size (Property)		
Program DOM: 0.07141 0.01141 0.01141 COMPARID DOM: 0.01141 0.01141 0.01141 PORE 64.11473 0.01141 0.01141 0.01141 COM COMPARID COMPARID 0.01141 0.01141						P001	4.6 ± 1.7	47+18	45+1.5	0.634												Dominee indicate	statistical significance		
						Pastaponarye Narcebe																			
POD 63-041 81-04-047 11-01 20 401 						Consumption (OME)																			
POD 441-737 645-851 641-833 0.644 Oblic = Cold Mark Equation CCN Second Sec						POD9	82.0 ± 61.8	\$5.6 + 64.9	T5.1 ± 55.2	0.215															
ONE - void Margine Episiatus, RNO - Naugeratin Day						PODI	651 ± 75.7	65.6 + 85.1	61.1 + 53.3	0.666															
With Control and Application Applications (Control and Control						OME - Ord Munching E.	and a state of the	Restoration Day																	
						Relativity of the Party of the	and as manufactors in	bounded within 6 way	to of common with a s	testing advanta															